NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. THIS PUBLICATION IS NEITHER AN OFFER TO BUY OR SELL NOR AN INVITATION TO TENDER OR OFFER TO BUY OR SELL SHARES.
As set out in paragraph 14 of Part 2 of the offer document posted on
Pursuant to Listing Rule 5.2.11, Consort announces that the cancellation notice period has now commenced and cancellation is expected to take effect from
As set out in the Offer Document, it is proposed that, following the Consort Shares being de-listed, Consort will be re-registered as a private company under the relevant provisions of the Companies Act.
Such cancellation and re-registration will significantly reduce the liquidity and marketability of any Consort Shares not assented to the Offer and their value may be affected as a consequence. Any remaining Consort Shareholders will become minority shareholders in a privately controlled limited company and may be unable to sell their Consort Shares and there can be no certainty that any dividends or other distributions would be made by Consort or that the Consort Shareholders would again be offered as much for the Consort Shares held by them as under the Offer. The Offer will remain open for acceptances until
Unless otherwise stated, the terms used in this announcement have the same meanings as given to them in the Offer Document.
[(1)] 20 Business Days after the date of this announcement.
[ ]
For more information please visit www.recipharm.com or contact:
This information is information that
About
For more information on
IMPORTANT INFORMATION
This publication is neither an offer to buy or sell nor an invitation to tender or offer to buy or sell shares.
The Offer will be implemented solely by means of the Offer Document and, in respect of Consort Shares held in certificated form, the Form of Acceptance accompanying the Offer Document, which will contain the full terms and conditions of the Offer including details of how to accept the Offer. Any approval, acceptance, decision or other response to the Offer should be made only on the basis of the information in the Offer Document and, in respect of Consort Shares held in certificated form, the Form of Acceptance. Consort Shareholders are strongly advised to read the formal documentation in relation to the Offer and each Consort Shareholder is urged to consult its independent professional adviser immediately regarding the tax consequences to it (or its beneficial owners) of the Offer.
This press release is not being published in or distributed to or into and must not be mailed or otherwise distributed or sent in or into any country in which the distribution or offering would require any such additional measures to be taken or would be in conflict with any law or regulation in such country. Persons who receive this press release (including, without limitation, nominees, trustees and custodians) and are subject to the law of any such jurisdiction will need to inform themselves about, and observe, any applicable restrictions or requirements. Any failure to do so may constitute a violation of the securities laws of any such jurisdiction.
To the extent this press release contains forward-looking statements, such statements do not represent facts and are characterized by the words "will", "expect", "believe", "estimate", "intend", "aim", "assume" or similar expressions. Such statements express the intentions, opinions or current expectations and assumptions of
Publication on a website
A copy of this announcement will be made available, subject to certain restrictions relating to persons resident in restricted jurisdictions, on
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com
http://publish.ne.cision.com//Release/ViewReleaseHtml/C777587EEF3B38EDE0C856B0705FC7D6
https://mb.cision.com/Main/9273/3029498/1189640.pdf
(c) 2020 Cision. All rights reserved., source